Pirfenidone, an Antifibrotic and Antiinflammatory Drug
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The aim of this study was to assess whether two-year treatment with Pirfenidone influence
necro-inflammation, fibrosis and steatosis in patients with chronic hepatitis C.